Skip to main content
. 2018 Feb 2;192(2):233–241. doi: 10.1111/cei.13093

Table 2.

Estimates for the mixed linear model

Effect Estimate Lower 95% CL* Upper 95% CL P‐value
Tryptophan
Intercept (µmol/l) 52·59 40·04 65·15 <·001
Therapy (bel versus tac ) (µmol/l) −1·10 −15·47 13·26 0·873
Days (µmol/l day) 0·16 −0·32 0·63 0·512
Days × therapy (bel versus tac) (µmol/l day) −0·13 −0·68 0·41 0·632
MMF (yes versus no) 12·25 −2·93 27·42 0·107
Kynurenine
Intercept (µmol/l) 2·69 1·83 3·55 < 0·001
Therapy (bel versus tac) (µmol/l) −0·24 −1·23 0·75 0·613
Days (µmol/L day) 0·00 −0·03 0·03 0·960
Days × therapy (bel versus tac) (µmol/l day) −0·01 −0·04 0·02 0·471
MMF (yes versus no) 0·61 −0·54 1·76 0·279
Kynurenine/tryptophan ratio
Intercept (µmol/l) 55·78 34·95 76·61 < 0·001
Therapy (bel versus tac) (µmol/l) −4·95 −28·84 18·94 0·668
Days (µmol/l day) −0·25 −1·00 0·51 0·519
Days × therapy (bel versus tac) (µmol/l day) 0·02 −0·86 0·89 0·969
MMF (yes versus no) 0 −26·39 22·98 0·886

*Confidence limit; belatacept; tacrolimus. MMF = mycophenolate mofetil.